(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 November 2011 (17.11.2011)

PCT

(10) International Publication Number
WO 2011/142621 A2

(51) International Patent Classification:
A61K 9/24 (2006.01) *A61K 31/40* (2006.01)
A61K 9/20 (2006.01) *A61P 3/06* (2006.01)
A61K 31/415 (2006.01) *A61P 3/00* (2006.01)

(21) International Application Number:
PCT/KR2011/003549

(22) International Filing Date:
13 May 2011 (13.05.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10-2010-0045636 14 May 2010 (14.05.2010) KR
10-2010-0053782 8 June 2010 (08.06.2010) KR

(71) Applicant *(for all designated States except US)*: **HANMI HOLDINGS CO., LTD.** [KR/KR]; #45, Bangi-dong, Songpa-gu, Seoul 138-828 (KR).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **KIM, Yong Il** [KR/KR]; Jinheung Apt. 147-2201, Hwaseo-dong, Paldal-gu, Suwon-si, Gyeonggi-do 442-718 (KR). **NA, Young Jun** [KR/KR]; 101-ho, #688-2, Hwaseo-dong, Paldal-gu, Suwon-si, Gyeonggi-do 442-150 (KR). **KIM, Min Jung** [KR/KR]; Hanyang Apt. 809-2502, Sanbon-dong, Gunpo-si, Gyeonggi-do 435-040 (KR). **KIM, Young-Hun** [KR/KR]; LG Village 209-706, Geumgok-dong, Gwonseon-gu, Suwon-si, Gyeonggi-do 441-704 (KR). **PARK, Jae Hyun** [KR/KR]; Dongsin Apt. 311-404, Cheongmyeongmaeul, Youngtong-dong, Youngtong-gu, Suwon-si, Gyeonggi-do 443-470 (KR). **WOO, Jong Soo** [KR/KR]; Cheoncheon Prugio Apt. 120-2303, Cheoncheon-dong, Jangan-gu, Suwon-si, Gyeonggi-do 440-710 (KR).

(74) Agent: **FIRSTLAW LEE & KO**; Trust Tower, 275-7 Yangjae-Dong, Seocho-Ku, Seoul 137-739 (KR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

(54) Title: PHARMACEUTICAL FORMULATION IN THE FORM OF BILAYERED TABLETS COMPRISING HMG-COA REDUCTASE INHIBITOR AND IRBESARTAN

FIG. 8



(57) Abstract: Provided is a pharmaceutical formulation in the form of bilayered tablets consisting of a first layer containing irbesartan or pharmaceutically acceptable salts thereof and a second layer containing an HMG-CoA reductase inhibitor and a basic additive, which can improve the dissolution rate and stability of irbesartan and an HMG-CoA reductase inhibitor to enhance the bioavailability of the drug compared to conventional complex formulations and to minimize the generation of the related compounds, thereby being effectively used as a stable and superior therapeutic agent for hypertension and hypercholesterolemia.

WO 2011/142621 A2